Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Atreca Inc Cl A (BCEL)

Atreca Inc Cl A (BCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Globe Newswire - Mon Aug 8, 2022

SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca to Present at Upcoming Investor Conferences Globe Newswire - Tue Aug 2, 2022

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer Business Wire - Mon Jun 27, 2022

Cellino Biotech, Inc. , an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as...

BCEL : 0.0900 (-1.32%)
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer Globe Newswire - Thu Jun 16, 2022

SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Announces Corporate Reorganization to Extend Cash Runway Globe Newswire - Wed Jun 1, 2022

Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets Extends cash runway through 2023 and reduces workforce by more than...

BCEL : 0.0900 (-1.32%)
Atreca to Present at Upcoming Investor Conferences Globe Newswire - Thu May 19, 2022

SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments Globe Newswire - Wed May 11, 2022

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101” Globe Newswire - Wed May 4, 2022

SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca to Present at Upcoming Virtual Investor Conferences Globe Newswire - Fri Apr 8, 2022

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Announces Expansion of Preclinical Pipeline Globe Newswire - Tue Apr 5, 2022

Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled...

BCEL : 0.0900 (-1.32%)

Barchart Exclusives

1 No-Brainer Value Stock That Looks Set to Recover From Its Slump Barchart - 48 minutes ago
PayPal's valuations look quite compelling after its massive underperformance, and the fintech name looks like a good value stock to buy at these price levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot